Cost effectiveness of an outpatient multidisciplinary pulmonary rehabilitation programme

BACKGROUND Pulmonary rehabilitation programmes improve the health of patients disabled by lung disease but their cost effectiveness is unproved. We undertook a cost/utility analysis in conjunction with a randomised controlled clinical trial of pulmonary rehabilitation versus standard care. METHODS Two hundred patients, mainly with chronic obstructive pulmonary disease, were randomly assigned to either an 18 visit, 6 week rehabilitation programme or standard medical management. The difference between the mean cost of 12 months of care for patients in the rehabilitation and control groups (incremental cost) and the difference between the two groups in quality adjusted life years (QALYs) gained (incremental utility) were determined. The ratio between incremental cost and utility (incremental cost/utility ratio) was calculated. RESULTS Each rehabilitation programme for up to 20 patients cost £12 120. The mean incremental cost of adding rehabilitation to standard care was £ –152 (95% CI –881 to 577) per patient, p=NS. The incremental utility of adding rehabilitation was 0.030 (95% CI 0.002 to 0.058) QALYs per patient, p=0.03. The point estimate of the incremental cost/utility ratio was therefore negative. The bootstrapping technique was used to model the distribution of cost/utility estimates possible from the data. A high likelihood of generating QALYs at negative or relatively low cost was indicated. The probability of the cost per QALY generated being below £0 was 0.64. CONCLUSIONS This outpatient pulmonary rehabilitation programme produces cost per QALY ratios within bounds considered to be cost effective and is likely to result in financial benefits to the health service.

[1]  A. Buist Guidelines for the management of chronic obstructive pulmonary disease. , 2002, Respiratory medicine.

[2]  G H Guyatt,et al.  Long-term effects of outpatient rehabilitation of COPD: A randomized trial. , 2000, Chest.

[3]  N. Payne,et al.  Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial , 2000, The Lancet.

[4]  R. Zuwallack,et al.  Pulmonary rehabilitation - 1999 , 1999 .

[5]  N. Ambrosino,et al.  Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. , 1999, The European respiratory journal.

[6]  M. Pearson Guidelines for the management of chronic obstructive pulmonary disease. , 1999, Caribbean health.

[7]  J. Brazier,et al.  Deriving a preference-based single index from the UK SF-36 Health Survey. , 1998, Journal of clinical epidemiology.

[8]  Philip D. Harvey,et al.  Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 , 1998, BMJ.

[9]  M. Morgan,et al.  A short outpatient pulmonary rehabilitation programme: immediate and longer-term effects on exercise performance and quality of life. , 1998, Respiratory medicine.

[10]  C. Phillips,et al.  THE ECONOMIC IMPLICATIONS OF IMPLEMENTING EVIDENCE‐BASED DIABETIC TREATMENT STRATEGIES , 1998, International journal of clinical practice.

[11]  A. Jacoby,et al.  A cost-utility analysis of interferon beta for multiple sclerosis. , 1998, Health technology assessment.

[12]  K. E. Bendstrup,et al.  Out-patient rehabilitation improves activities of daily living, quality of life and exercise tolerance in chronic obstructive pulmonary disease. , 1997, The European respiratory journal.

[13]  B. Tiep Disease management of COPD with pulmonary rehabilitation. , 1997, Chest.

[14]  J. Brazier,et al.  Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. , 1997, Thorax.

[15]  J. Pounsford,et al.  Outpatient Pulmonary Rehabilitation in Severe Chronic Obstructive Pulmonary Disease , 1997, Journal of the Royal College of Physicians of London.

[16]  G. Guyatt,et al.  Economic analysis of respiratory rehabilitation. , 1997, Chest.

[17]  A H Briggs,et al.  Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. , 1997, Health economics.

[18]  M. Wittmann [Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease]. , 1997, Pneumologie.

[19]  J. Bach,et al.  The cost/benefits of outpatient-based pulmonary rehabilitation. , 1997, Archives of physical medicine and rehabilitation.

[20]  P. Sly,et al.  Allergic respiratory disease: strategic targets for primary prevention during childhood. , 1997, Thorax.

[21]  H. Kemper,et al.  The effects of a community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a randomized controlled trial. , 1997, The European respiratory journal.

[22]  A. Netten,et al.  Unit Costs of Health and Social Care 1997 , 1996 .

[23]  D. Mahler,et al.  Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with COPD. , 1995, Chest.

[24]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[25]  A. Ries,et al.  Effects of Pulmonary Rehabilitation on Physiologic and Psychosocial Outcomes in Patients with Chronic Obstructive Pulmonary Disease , 1995, Annals of Internal Medicine.

[26]  A. Stevens,et al.  'Quick and clean': authoritative health technology assessment for local health care contracting. , 1995, Health trends.

[27]  G. Guyatt,et al.  Randomised controlled trial of respiratory rehabilitation , 1994, The Lancet.

[28]  M J Al,et al.  Costs, effects and C/E-ratios alongside a clinical trial. , 1994, Health economics.

[29]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[30]  Ware J.E.Jr.,et al.  THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION , 1992 .

[31]  A. Maynard DEVELOPING THE HEALTH CARE MARKET , 1991 .

[32]  I. Kawachi,et al.  The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. , 1991, Journal of hypertension.

[33]  G. Guyatt,et al.  A measure of quality of life for clinical trials in chronic lung disease. , 1987, Thorax.

[34]  J. Bush,et al.  Policy space areas and properties of benefit-cost/utility analysis. , 1986, JAMA.